- Home
- ABBV
ABBV
AbbVie Inc.
as 09-17-2025 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 365.1B | IPO Year: | N/A |
| Target Price: | $224.41 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.10 | EPS Growth: | -29.76 |
| 52 Week Low/High: | $163.81 - $221.76 | Next Earning Date: | 10-29-2025 |
| Revenue: | $58,328,000,000 | Revenue Growth: | 6.05% |
| Revenue Growth (this year): | 9.86% | Revenue Growth (next year): | 8.90% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SALEKI-GERHARDT AZITA | ABBV | EVP, CHIEF OPERATIONS OFFICER | Aug 12 '25 | Sell | $198.42 | 42,370 | $8,407,055.40 | 177,292 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
The Fly
14 hours ago
Netflix upgraded, Five Below initiated: Wall Street's top analyst calls
Investor's Business Daily
14 hours ago
Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker
MT Newswires
18 hours ago
Berenberg Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $270 From $170
Insider Monkey
a day ago
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227
Zacks
2 days ago
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
Insider Monkey
2 days ago
AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends
Simply Wall St.
2 days ago
Assessing AbbVie After Neuro Pipeline Expansion and Double Digit 2025 Share Gains
MT Newswires
2 days ago
JPMorgan Adjusts Price Target on AbbVie to $235 From $200, Maintains Overweight Rating
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.